After several years of poor performance, Bristol Myers Squibb (NYSE: BMY) is bouncing back.
The company's shares are up 42% over the trailing 12-month period, while the S&P 500 has climbed just 15%. Could there be more upside ahead for the pharmaceutical giant? There are some reasons to think so. Bristol Myers is trading at just 9. 4x forward earnings, versus an average of 18. 5x for healthcare stocks. Is Bristol Myers a great value play to buy now? Image source: The Motley Fool.